Drug development entails risk. Clinical trials are elaborate and expensive experiments, and unfortunately sometimes promising hypotheses prove false. This … Read more
Myrtle Potter was appointed Vant Operating Chair for Roivant Pharma in July 2018. In this role, she is responsible for the oversight of the biopharmaceutical companies in the Roivant Family. She serves as one of two Roivant representatives on these boards and is chairman of the board for half of the companies. Ms. Potter previously served as President and Chief Operating Officer of Genentech during a pivotal period of the company’s growth. Under her leadership, Genentech achieved record sales and earnings growth each year. Prior to Genentech she was president of Bristol-Myers Squibb’s U.S. Cardiovascular and Metabolic business. She is a graduate of the University of Chicago and serves on the university’s board of trustees. She also serves on the board of Liberty Mutual Insurance Group, and previously served on the boards of Amazon, Express Scripts, and Medco Health Solutions.